New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Nektar Therapeutics (Nasdaq: NKTR) today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking ...

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data ...

People abused by intimate partners have worse asthma – but researchers are still untangling the reasons behind this surprising link

Uncontrolled inflammation is usually thought to be the culprit behind asthma. But in asthma patients who have survived ...
Healio

Asthma control improves with tezepelumab, reduced oral corticosteroid use

Patients who depended on oral corticosteroids to care for their severe asthma experienced improvements in asthma control ...

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine ...

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically ...
Healio

Omalizumab leads biologics in adverse effect risks during asthma treatment

Omalizumab had the greatest risk for adverse effects and dupilumab had the most favorable safety profile among biologics for patients with asthma, according to an abstract presented at the CHEST ...
Jacobs School of Medicine and Biomedical Sciences - University at Buffalo

An In-Depth Look at Asthma, a Mystery Disease of Sorts

The 2025 Lawrence and Nancy Golden Memorial Lectureship on Mind-Body Medicine focused on the psychobiology of asthma.

Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3

RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, ...

Staloral(R) Birch Phase III Study Successfully Meets Primary Endpoint, Demonstrating Efficacy in Children and Adolescents

Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of ...
The Journalist's Resource

Food allergies in children: An explainer

New evidence suggests that introducing common sources of food allergies in the first year of life is associated with reductions in new cases in children. But prevention is only part of the story.

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma & ...